• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

术前化疗可能通过胃癌患者的术后并发症改变复发模式。

Preoperative chemotherapy could modify recurrence patterns through postoperative complications in patients with gastric cancer.

机构信息

Department of Upper Gastrointestinal Surgery, Kitasato University School of Medicine, Kitasato 1-15-1, Minami-ku, Sagamihara, 252-0374, Japan.

Department of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Japan.

出版信息

Langenbecks Arch Surg. 2021 Jun;406(4):1045-1055. doi: 10.1007/s00423-021-02153-5. Epub 2021 Mar 20.

DOI:10.1007/s00423-021-02153-5
PMID:33745003
Abstract

PURPOSE

Postoperative infectious complications have a negative impact on survival outcomes in patients with gastric cancer. It is recently reported that preoperative chemotherapy may eliminate this negative impact. This study aimed to confirm whether preoperative chemotherapy can eliminate the negative impact of postoperative infectious complications (IC) on survival outcomes and elucidate the association between postoperative infectious complications and recurrence patterns.

METHODS

We retrospectively reviewed data of 86 patients who received preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by R0 gastrectomy at the Kitasato University between 2006 and 2016. Patients who developed grade II or higher infectious complications during hospitalization were grouped into the IC group, while others were grouped into the non-IC (NIC) group. Survival outcomes and recurrence patterns were analyzed between the two groups.

RESULTS

Infectious complications with Clavien-Dindo classification of grade II or higher were found in 12 patients (14.0%, IC group). The median observational period was 61 months. Overall survival and progression-free survival were similar in the IC and NIC groups. Recurrence occurred in 39 patients. The proportions of peritoneal and lymph node recurrences were not significantly different between the two groups. However, the proportion of distant metastasis in the IC group was significantly higher than that in NIC group (3/4 [75%] vs. 9/35 [17%], p = 0.04).

CONCLUSIONS

Pathological stage after neoadjuvant therapy plays a stronger role in recurrence than postoperative complications. Lymph node and peritoneal metastasis may be suppressed by preoperative chemotherapy.

摘要

目的

术后感染并发症会对胃癌患者的生存结果产生负面影响。最近有报道称,术前化疗可能消除这种负面影响。本研究旨在确认术前化疗是否可以消除术后感染并发症(IC)对生存结果的负面影响,并阐明术后感染并发症与复发模式之间的关系。

方法

我们回顾性分析了 2006 年至 2016 年在北里大学接受多西他赛、顺铂和 S-1 术前化疗后行 R0 胃切除术的 86 例患者的数据。在住院期间发生 II 级或更高等级感染并发症的患者分为感染组(IC 组),其余患者分为非感染组(NIC 组)。分析两组之间的生存结果和复发模式。

结果

12 例(14.0%)患者出现 Clavien-Dindo 分级 II 级或更高的感染并发症(IC 组)。中位观察期为 61 个月。IC 组和 NIC 组的总生存率和无进展生存率相似。39 例患者发生复发。两组腹膜和淋巴结复发的比例无显著差异。然而,IC 组的远处转移比例明显高于 NIC 组(3/4[75%]比 9/35[17%],p=0.04)。

结论

新辅助治疗后的病理分期比术后并发症对复发的影响更大。淋巴结和腹膜转移可能被术前化疗抑制。

相似文献

1
Preoperative chemotherapy could modify recurrence patterns through postoperative complications in patients with gastric cancer.术前化疗可能通过胃癌患者的术后并发症改变复发模式。
Langenbecks Arch Surg. 2021 Jun;406(4):1045-1055. doi: 10.1007/s00423-021-02153-5. Epub 2021 Mar 20.
2
[Postoperative complications and their influence on the prognosis factors in gastric cancer patients receiving neoadjuvant treatment].[接受新辅助治疗的胃癌患者术后并发症及其对预后因素的影响]
Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Feb 25;24(2):160-166. doi: 10.3760/cma.j.cn.441530-20200420-00229.
3
[Clinical features and prognosis analysis of 21 gastric cancer patients with pathological complete response after neoadjuvant chemotherapy].21例胃癌患者新辅助化疗后病理完全缓解的临床特征及预后分析
Zhonghua Wei Chang Wai Ke Za Zhi. 2017 Oct 25;20(10):1168-1173.
4
Outcomes of preoperative S-1 and docetaxel combination chemotherapy in patients with locally advanced gastric cancer.术前 S-1 和多西他赛联合化疗治疗局部进展期胃癌的疗效。
Cancer Chemother Pharmacol. 2019 Jun;83(6):1047-1055. doi: 10.1007/s00280-019-03813-6. Epub 2019 Mar 25.
5
[Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].奥沙利铂联合卡培他滨或奥沙利铂联合S-1新辅助化疗治疗进展期胃癌的安全性和有效性
Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Feb 25;24(2):138-144. doi: 10.3760/cma.j.cn.441530-20200721-00433.
6
[Risk factors of postoperative complication after total gastrectomy in advanced gastric cancer patients receiving neoadjuvant chemotherapy].[接受新辅助化疗的进展期胃癌患者全胃切除术后并发症的危险因素]
Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Feb 25;24(2):153-159. doi: 10.3760/cma.j.cn.441530-20200905-00512.
7
A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002.一项多西他赛、顺铂和S-1术前化疗联合D2根治术加主动脉旁淋巴结清扫术治疗伴有广泛淋巴结转移的胃癌的II期研究:JCOG1002
Gastric Cancer. 2017 Mar;20(2):322-331. doi: 10.1007/s10120-016-0619-z. Epub 2016 Jun 14.
8
Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination.新辅助腹腔内和全身化疗治疗伴有腹膜转移的胃癌患者。
Ann Surg Oncol. 2011 Dec;18(13):3726-31. doi: 10.1245/s10434-011-1770-8. Epub 2011 May 17.
9
Role of D2 gastrectomy in gastric cancer with clinical para-aortic lymph node metastasis.D2 胃切除术在伴有临床腹腔动脉旁淋巴结转移的胃癌中的作用。
World J Gastroenterol. 2019 May 21;25(19):2338-2353. doi: 10.3748/wjg.v25.i19.2338.
10
[Conversion Surgery for Stage IV Gastric Cancer].[IV期胃癌的转化性手术]
Gan To Kagaku Ryoho. 2017 Nov;44(12):1208-1210.

引用本文的文献

1
Nomogram to predict overall survival of patients receiving radical gastrectomy and incomplete peri-operative adjuvant chemotherapy for stage II/III gastric cancer: a retrospective bi-center cohort study.列线图预测接受根治性胃切除术和不完全围手术期辅助化疗的 II/III 期胃癌患者的总生存期:一项回顾性双中心队列研究。
BMC Cancer. 2024 Mar 18;24(1):344. doi: 10.1186/s12885-024-12103-1.
2
Impact of Systematic Holistic Nursing Combined with Narrative Nursing Intervention for Patients with Advanced Gastric Cancer on Complications and Negative Emotions.系统整体护理联合叙事护理干预对晚期胃癌患者并发症及负性情绪的影响
Evid Based Complement Alternat Med. 2022 Jul 15;2022:9148843. doi: 10.1155/2022/9148843. eCollection 2022.

本文引用的文献

1
Comparison on Clinicopathological Features, Treatments and Prognosis between Proximal Gastric Cancer and Distal Gastric Cancer: A National Cancer Data Base Analysis.近端胃癌与远端胃癌的临床病理特征、治疗及预后比较:一项国家癌症数据库分析
J Cancer. 2019 Jun 2;10(14):3145-3153. doi: 10.7150/jca.30371. eCollection 2019.
2
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.氟尿嘧啶+亚叶酸、奥沙利铂和多西紫杉醇与氟尿嘧啶或卡培他滨+顺铂和表柔比星用于局部晚期可切除胃或胃食管交界处腺癌的围手术期化疗(FLOT4):一项随机、2/3 期试验。
Lancet. 2019 May 11;393(10184):1948-1957. doi: 10.1016/S0140-6736(18)32557-1. Epub 2019 Apr 11.
3
Does neoadjuvant chemotherapy cancel out the negative survival impact induced by surgical complications after gastrectomy?新辅助化疗是否能消除胃切除术后手术并发症导致的生存负面影响?
Gastric Cancer. 2019 Nov;22(6):1274-1284. doi: 10.1007/s10120-019-00957-5. Epub 2019 Apr 3.
4
Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial.多西他赛联合口服氟嘧啶可提高 III 期胃癌患者的疗效:JACCRO GC-07 随机对照试验的中期分析。
J Clin Oncol. 2019 May 20;37(15):1296-1304. doi: 10.1200/JCO.18.01138. Epub 2019 Mar 29.
5
Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501).随机 III 期临床试验:胃切除术联合或不联合新辅助 S-1 加顺铂治疗 4 型或大型 3 型胃癌的短期安全性和手术结果:日本临床肿瘤学组研究(JCOG0501)。
Gastric Cancer. 2019 Sep;22(5):1044-1052. doi: 10.1007/s10120-019-00941-z. Epub 2019 Mar 2.
6
A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1, followed by gastrectomy with D2 lymph node dissection for high-risk advanced gastric cancer: results of the KDOG1001 trial.一项新辅助化疗联合多西他赛、顺铂和 S-1,继以 D2 淋巴结清扫术治疗高危进展期胃癌的 II 期研究:KDOG1001 试验结果。
Gastric Cancer. 2019 May;22(3):598-606. doi: 10.1007/s10120-018-0884-0. Epub 2018 Oct 3.
7
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
8
Prophylactic effect of neoadjuvant chemotherapy in gastric cancer patients with postoperative complications.新辅助化疗对胃癌术后并发症患者的预防作用。
Gastric Cancer. 2018 Jul;21(4):703-709. doi: 10.1007/s10120-017-0781-y. Epub 2017 Nov 29.
9
Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma.评估近端胃癌全胃切除术中脾切除术的随机对照试验
Ann Surg. 2017 Feb;265(2):277-283. doi: 10.1097/SLA.0000000000001814.
10
Prognostic Impact of Postoperative Morbidity After Esophagectomy for Esophageal Cancer: Exploratory Analysis of JCOG9907.食管癌切除术术后并发症对预后的影响:JCOG9907 的探索性分析。
Ann Surg. 2017 Jun;265(6):1152-1157. doi: 10.1097/SLA.0000000000001828.